GlaxoSmithKline, Britain’s biggest drugmaker, is placing a small but important bet on a new way of treating diseases by targeting electrical signals in the body.
The company said on Wednesday it would offer a $1 million prize to stimulate innovation in the field, as well as funding up to 40 researchers working in external laboratories.
{iframe}http://uk.reuters.com/article/2013/04/10/us-glaxosmithkline-electroceuticals-idUKBRE9390VM20130410{/iframe}